Highnoon Laboratories Limited (PSX:HINOON)
971.90
-6.12 (-0.63%)
At close: Nov 6, 2026
Highnoon Laboratories Revenue
Highnoon Laboratories had revenue of 7.51B PKR in the quarter ending September 30, 2026, with 8.75% growth. This brings the company's total for the last twelve months to 28.89B, up 9.42% year-over-year. In the year 2025, Highnoon Laboratories had annual revenue of 27.71B with 12.44% growth. That makes Highnoon Laboratories the 22,341st largest company in the world by revenue and 139th in Pakistan.
Revenue (ttm)
28.89B
Revenue Growth
+9.42%
P/S Ratio
1.79
Revenue / Employee
11.27M
Employees
2,563
Market Cap
51.49B
Revenue by Geography
- Pakistan 24.77B 91.9%
- Afghanistan 1.62B 6.0%
- United Arab Emirates 298.27M 1.1%
- Sri Lanka 93.82M 0.3%
- France 84.20M 0.3%
- Sudan 38.55M 0.1%
- Others 21.39M 0.1%
- Other 25.06M 0.1%
Fiscal year ended Dec 31, 2025 See the full Highnoon Laboratories breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.71B | 3.06B | 12.44% |
| Dec 31, 2024 | 24.64B | 4.87B | 24.66% |
| Dec 31, 2023 | 19.77B | 3.95B | 24.98% |
| Dec 31, 2022 | 15.82B | 2.82B | 21.65% |
| Dec 31, 2021 | 13.00B | 2.30B | 21.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories (Pakistan) | 77.83B |
| GlaxoSmithKline Pakistan | 69.53B |
| The Searle Company | 38.29B |
| AGP Limited | 26.52B |
| Ferozsons Laboratories | 25.09B |
| Citi Pharma | 14.22B |
| Macter International | 12.50B |
| Otsuka Pakistan | 4.18B |